Patents by Inventor Leander Grode

Leander Grode has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma
    Publication number: 20240277825
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of bladder carcinoma, particularly in the second-line treatment of non-muscle-invasive bladder carcinoma.
    Type: Application
    Filed: July 20, 2022
    Publication date: August 22, 2024
    Applicants: SERUM LIFE SCIENCE EUROPE GMBH, SERUM INSTITUTE OF INDIA LTD.
    Inventor: Leander GRODE
  • Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
    Patent number: 11426453
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: August 30, 2022
    Assignee: Vakzine Projekt Management GmbH
    Inventor: Leander Grode
  • Recombinant Mycobacterium as an Immunotherapeutic Agent for the Treatment of Cancer
    Publication number: 20220160858
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Application
    Filed: February 9, 2022
    Publication date: May 26, 2022
    Applicant: VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander GRODE
  • Recombinant Mycobacterium as an Immunotherapeutic Agent for the Treatment of Cancer
    Publication number: 20200179502
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Application
    Filed: November 19, 2019
    Publication date: June 11, 2020
    Applicant: VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander GRODE
  • Recombinant as an immunotherapeutic agent for the treatment of cancer
    Patent number: 10525118
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: January 7, 2020
    Assignee: Vakzine Projekt Management GmbH
    Inventor: Leander Grode
  • Recombinant Mycobacterium as an Immunotherapeutic Agent for the Treatment of Cancer
    Publication number: 20180200357
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Application
    Filed: May 3, 2016
    Publication date: July 19, 2018
    Applicant: VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander GRODE
  • Recombinant as a vaccine
    Patent number: 9879268
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 30, 2018
    Assignees: Vakzine Projekt Management GmbH, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christine Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • RECOMBINANT MYCOBACTERIUM AS A VACCINE
    Publication number: 20160184419
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Application
    Filed: March 4, 2016
    Publication date: June 30, 2016
    Applicants: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christine DESEL, Stefan H.E. Kaufmann, Silke Bandermann, Leander Grode
  • Recombinant mycobacterium as a vaccine
    Patent number: 9328350
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: May 3, 2016
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • Recombinant mycobacterium as vaccine for use in humans
    Patent number: 9084749
    Abstract: The invention relates to a recombinant vaccine providing protective immunity especially against tuberculosis in human subjects.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: July 21, 2015
    Assignee: Vakzine Projekt Management GmbH
    Inventor: Leander Grode
  • Combination of a bacterial cell and a biologically active agent
    Patent number: 9078844
    Abstract: The present invention is related to a combination comprising a first constituent and a second constituent, wherein the first constituent is a bacterial cell which comprises at least one recombinant nucleic acid molecule encoding a phagolysosomal escape peptide or polypeptide; and wherein the second constituent is a biologically active agent. In certain embodiments, the combination is of use as a vaccine to induce an immune response in a mammal.
    Type: Grant
    Filed: October 16, 2005
    Date of Patent: July 14, 2015
    Assignee: VAKZINE PROJEKT MANAGEMENT GMBH
    Inventors: Albrecht Läufer, Bernd Eisele, Leander Grode
  • Determination of the efficacy of an anti-mycobacterial vaccination
    Patent number: 8906389
    Abstract: The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: December 9, 2014
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • RECOMBINANT MYCOBCTERIUM AS A VACCINE
    Publication number: 20130337011
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 19, 2013
    Applicants: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H.E. Kaufmann, Silke Bandermann, Leander Grode
  • RECOMBINANT MYCOBACTERIUM AS VACCINE FOR USE IN HUMANS
    Publication number: 20130280287
    Abstract: The invention relates to a recombinant vaccine providing protective immunity especially against tuberculosis in human subjects.
    Type: Application
    Filed: September 16, 2011
    Publication date: October 24, 2013
    Applicant: VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander Grode
  • DETERMINATION OF THE EFFICACY OF AN ANTI-MYCOBACTERIAL VACCINATION
    Publication number: 20130280739
    Abstract: The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 24, 2013
    Applicants: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H.E. Kaufmann, Silke Bandermann, Leander Grode
  • Tuberculosis vaccine with improved efficacy
    Patent number: 8545854
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: October 1, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenshaften, e.V.
    Inventors: Leander Grode, Stefan H. E. Kaufmann, Baerbel Raupach, Juergen Hess
  • COMPOSITION CONTAINING HCMV PARTICLES
    Publication number: 20130045230
    Abstract: The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 21, 2013
    Applicants: RHEIN BIOTECH GMBH, VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander GRODE
  • COMPOSITION CONTAINING HCMV PARTICLES
    Publication number: 20130028935
    Abstract: The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 31, 2013
    Applicants: RHEIN BIOTECH GMBH, VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander GRODE
  • TUBERCULOSIS VACCINE WITH IMPROVED EFFICACY
    Publication number: 20120027794
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Application
    Filed: June 22, 2011
    Publication date: February 2, 2012
    Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Leander GRODE, Stefan H.E. KAUFMANN, Barbel RAUPACH, Jürgen HESS
  • Tuberculosis vaccine with improved efficacy
    Patent number: 7988980
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: August 2, 2011
    Assignee: Max-Planck-Gesellschaft zur Foerderung Der Wissenshaften e. V.
    Inventors: Leander Grode, Stefan H. E. Kaufmann, Bärbel Raupach, Jürgen Hess